The Management Boardof Medinice S.A., with its registered office in Warsaw (the "Issuer"),hereby informs that on 27 April 2026 the Issuer signed a Term Sheet witha foreign entity based in the DACH region. The partner has over 15 yearsof experience in the MedTech sector, specializing in the development ofmedical devices and R_D in cardiology and cardiac surgery, includingprojects involving PFA (Pulsed Field Ablation) technology. Its portfoliohas been developed in cooperation with leading global industry players.

Underthe Term Sheet, the Issuer intends to acquire a majority stake in thetarget. The execution of a final investment agreement-covering, amongother things, price, payment terms, closing conditions andpost-transaction cooperation-will be subject to a comprehensive duediligence process and is expected by 30 September 2026. Until that time,the Issuer has been granted exclusivity for negotiations regarding thepotential acquisition.

The signing of theTerm Sheet marks another step in the execution of the Issuer's strategy,focused on developing minimally invasive solutions for cardiology andcardiac surgery, while expanding its portfolio into two high-potentialMedTech segments: PFA and robotic surgical systems.